Stephen H. Lockhart
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
NRC Health dividend and governance topics in focus. Recent coverage highlights NRC Health's dividend profile and broader discussions on hospital board governance. The stock is currently trading with a low RSI and near a key support level, reflecting cautious sentiment. These articles provide context on the company's financial policies and industry standards rather than reporting on a specific corporate event.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
Transaction History
| MOH | ▲ Buy | Grant | 304 | $55K | 10/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 237 | $55K | 7/1/2026 | View on chart |
| NRC | ▲ Buy | Grant | 7,697 | $0 | 6/23/2026 | View on chart |
| WST | ▲ Buy | Grant | 791 | $0 | 5/4/2026 | View on chart |
| MOH | ▲ Buy | Grant | 405 | $55K | 4/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 317 | $55K | 1/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 285 | $55K | 10/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 180 | $55K | 7/1/2025 | View on chart |
| WST | ▲ Buy | Grant | 1,071 | $0 | 5/6/2025 | View on chart |
| MOH | ▲ Buy | Grant | 168 | $55K | 4/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 189 | $55K | 1/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 161 | $55K | 10/1/2024 | View on chart |
| MOH | ▲ Buy | Grant | 188 | $55K | 7/1/2024 | View on chart |
| WST | ▲ Buy | Grant | 564 | $0 | 4/23/2024 | View on chart |
| MOH | ▲ Buy | Grant | 136 | $55K | 4/1/2024 | View on chart |
| MOH | ▲ Buy | Grant | 152 | $55K | 1/1/2024 | View on chart |
| MOH | ▲ Buy | Grant | 168 | $55K | 10/1/2023 | View on chart |
| MOH | ▲ Buy | Grant | 183 | $55K | 7/1/2023 | View on chart |
| WST | ▲ Buy | Grant | 616 | — | 4/25/2023 | View on chart |
| MOH | ▲ Buy | Grant | 206 | $55K | 4/1/2023 | View on chart |
| MOH | ▲ Buy | Grant | 167 | $55K | 1/1/2023 | View on chart |
| MOH | ▲ Buy | Grant | 167 | $55K | 10/1/2022 | View on chart |
| WST | ▲ Buy | Grant | 454 | — | 8/1/2022 | View on chart |
| MOH | ▲ Buy | Grant | 194 | $55K | 7/1/2022 | View on chart |
| MOH | ▲ Buy | Grant | 162 | $55K | 4/1/2022 | View on chart |
| MOH | ▲ Buy | Grant | 173 | $55K | 1/1/2022 | View on chart |
| MOH | ▲ Buy | Grant | 203 | $55K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Molina Healthcare Draws Value Investor Interest Amid Recent Pressure
Diamond Hill Capital has highlighted long-term value in Molina Healthcare following recent stock price pressure. This view is echoed by other market analyses questioning if the stock is a value play. The company is currently trading near its 52-week low, with an average analyst target of $209.12.
Molina Healthcare Draws Value Investor Interest Amid Recent Pressure. Diamond Hill Capital has highlighted long-term value in Molina Healthcare following recent stock price pressure. This view is echoed by other market analyses questioning if the stock is a value play. The company is currently trading near its 52-week low, with an average analyst target of $209.12.